Prostate cancer that is no longer stopped by low testosterone levels is called castration-resistant. Castration-resistant prostate cancer is a type of prostate cancer in which the patient’s PSA level is rising and the cancer has spread to other areas of the body. If the cancer has not spread to other parts of the body, it is called non-metastatic castration-resistant prostate cancer.1
What is non-metastatic castration-resistant prostate cancer (nmCRPC)?
Non-metastatic castration-resistant prostate cancer (nmCRPC) is a type of prostate cancer in which:
The cancer has not metastasized (spread) to other areas of the body
The cancer is no longer responding to medical or surgical treatment that lowers testosterone (ADT) and
The patient is continuing to have rising PSA levels (prostate-specific antigen) even when having low testosterone levels in the blood1
Treatment options for nmCRPC
The treatment landscape for nmCRPC is evolving and the Food and Drug Administration (FDA) has approved 2 anti-androgens for nmCRPC, Erleada (apalutamide) and Xtandi (enzalutamide), both for delaying metastases. These novel androgen-modulating drugs provide promise for prolonging progression-free survival (PFS) for patients.2
Cancer.net. Prostate Cancer: Types of Treatment. Accessed online August 8th, 2019. https://www.cancer.net/cancer-types/prostate-cancer/types-treatment
El-Amm, J. Aragon-Ching, J.B. The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer. March 2019. Accessed online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407161/.